BALAXI PHARMACEUTICALS LIMITED (BALAXI) - Total Assets
Based on the latest financial reports, BALAXI PHARMACEUTICALS LIMITED (BALAXI) holds total assets worth Rs3.37 Billion INR (≈ $36.45 Million USD) as of March 2026. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments.
BALAXI PHARMACEUTICALS LIMITED - Total Assets Trend (2013–2026)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's total assets have evolved over time, based on quarterly financial data. Also see BALAXI market cap for the company's overall valuation and market capitalisation.
BALAXI PHARMACEUTICALS LIMITED - Asset Composition Analysis
Current Asset Composition (March 2026)
BALAXI PHARMACEUTICALS LIMITED's total assets of Rs3.37 Billion consist of 44.7% current assets and 55.3% non-current assets. Review BALAXI PHARMACEUTICALS LIMITED debt and liabilities to assess the company's total debt and financial obligations.
| Asset Category | Amount (INR) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | Rs0.00 | 4.3% |
| Accounts Receivable | Rs1.36 Billion | 40.4% |
| Inventory | Rs834.80 Million | 24.8% |
| Property, Plant & Equipment | Rs0.00 | 0.0% |
| Intangible Assets | Rs326.71 Million | 9.7% |
| Goodwill | Rs326.71 Million | 9.7% |
Asset Composition Trend (2013–2026)
This chart illustrates how BALAXI PHARMACEUTICALS LIMITED's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. See latest BALAXI PHARMACEUTICALS LIMITED stock price today for real-time trading data and today's change.
Key Asset Composition Facts
- Current vs. Non-Current Assets: BALAXI PHARMACEUTICALS LIMITED's current assets represent 44.7% of total assets in 2026, a decrease from 62.1% in 2013.
- Cash Position: Cash and equivalents constituted 4.3% of total assets in 2026, down from 42.9% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is accounts receivable at 40.4% of total assets.
BALAXI PHARMACEUTICALS LIMITED Competitors by Total Assets
Key competitors of BALAXI PHARMACEUTICALS LIMITED based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Swedish Orphan Biovitrum AB (publ)
ST:SOBI
|
Sweden | Skr81.26 Billion |
|
Yunnan Baiyao Group Co Ltd
SHE:000538
|
China | CN¥53.34 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Harbin Gloria Pharmaceuticals
SHE:002437
|
China | CN¥3.14 Billion |
|
Jiuzhitang Co Ltd
SHE:000989
|
China | CN¥5.73 Billion |
|
Renhe Pharmacy Co Ltd
SHE:000650
|
China | CN¥7.93 Billion |
|
Jiangsu Kanion Pharmaceutical Co Ltd
SHG:600557
|
China | CN¥6.74 Billion |
BALAXI PHARMACEUTICALS LIMITED - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 4.51 | 4.45 | 2.70 |
| Quick Ratio | 2.01 | 3.01 | 2.31 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | Rs1.17 Billion | Rs1.88 Billion | Rs590.78 Million |
BALAXI PHARMACEUTICALS LIMITED - Advanced Valuation Insights
This section examines the relationship between BALAXI PHARMACEUTICALS LIMITED's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 0.54 |
| Latest Market Cap to Assets Ratio | 0.00 |
| Asset Growth Rate (YoY) | 8.6% |
| Total Assets | Rs3.37 Billion |
| Market Capitalization | $14.06 Million USD |
Valuation Analysis
Below Book Valuation: The market values BALAXI PHARMACEUTICALS LIMITED's assets below their book value (0.00x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: BALAXI PHARMACEUTICALS LIMITED's assets grew by 8.6% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for BALAXI PHARMACEUTICALS LIMITED (2013–2026)
The table below shows the annual total assets of BALAXI PHARMACEUTICALS LIMITED from 2013 to 2026.
| Year | Total Assets | Change |
|---|---|---|
| 2026-03-31 | Rs3.37 Billion ≈ $36.45 Million |
+8.60% |
| 2025-03-31 | Rs3.10 Billion ≈ $33.56 Million |
+20.13% |
| 2024-03-31 | Rs2.58 Billion ≈ $27.94 Million |
+7.79% |
| 2023-03-31 | Rs2.40 Billion ≈ $25.92 Million |
+35.81% |
| 2022-03-31 | Rs1.76 Billion ≈ $19.08 Million |
+77.04% |
| 2021-03-31 | Rs996.80 Million ≈ $10.78 Million |
+177.11% |
| 2020-03-31 | Rs359.71 Million ≈ $3.89 Million |
+488.93% |
| 2019-03-31 | Rs61.08 Million ≈ $660.54K |
+262.13% |
| 2018-03-31 | Rs16.87 Million ≈ $182.41K |
-34.54% |
| 2017-03-31 | Rs25.77 Million ≈ $278.65K |
+7117.47% |
| 2016-03-31 | Rs356.99K ≈ $3.86K |
-3.02% |
| 2015-03-31 | Rs368.10K ≈ $3.98K |
-96.94% |
| 2014-03-31 | Rs12.04 Million ≈ $130.21K |
-2.76% |
| 2013-03-31 | Rs12.38 Million ≈ $133.91K |
-- |
About BALAXI PHARMACEUTICALS LIMITED
Balaxi Pharmaceuticals Limited engages in the international wholesale distribution of pharmaceuticals, builders hardware, and FMCG products in India, Africa, and Latin America. The company offers pharmaceutical products across various therapeutic areas, including antibiotics, analgesic, anti-malaria, and others. It also provides biscuits and toothpaste. The company was formerly known as Balaxi Ve… Read more